FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to therapy and can be used for undifferentiated connective displasy (UCD) correction. Method involves introduction of the medicinal agent intended for normalising gut organisms and containing bifidus bacteria in therapeutic doses 20-30 min before meals within 3-4 weeks.
EFFECT: when prescribed, the medicinal agent containing bifidus bacteria allows for direct connective metabolism control thus lowering and improving activity of the antioxidant systems.
6 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CORRECTION OF NON-DIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA | 2005 |
|
RU2290175C2 |
| METHOD OF CORRECTION OF VIOLATIONS OF METABOLIC PROCESSES IN CONNECTIVE TISSUE | 2018 |
|
RU2680389C1 |
| METHOD FOR PREVENTING COMPLICATIONS OF PERINATAL PERIOD | 2020 |
|
RU2761315C1 |
| METHOD OF CORRECTION OF DIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA IN ADOLESCENTS AND ADULTS | 2018 |
|
RU2680390C1 |
| METHOD FOR TREATMENT OF ADOLESCENTS WITH UNDIFFERENTIATED DYSPLASIA OF CONNECTING TISSUE | 2016 |
|
RU2623451C1 |
| METHOD FOR ASSESSING RISK OF UNDIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA | 2015 |
|
RU2578961C1 |
| METHOD OF AGE-SPECIFIC THERAPY AND PREVENTION OF CONNECTIVE TISSUE DYSPLASIA | 2016 |
|
RU2657751C1 |
| METHOD FOR DIAGNOSTICS OF NON-DIFFERENTIAL CONNECTIVE TISSUE DYSPLASIA IN PREGNANT WOMEN | 2016 |
|
RU2639820C1 |
| METHOD OF DIAGNOSING SEVERITY DEGREE OF SYNDROME OF NON-DIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA | 2010 |
|
RU2455940C1 |
| 0 |
|
SU1777882A1 |
